Literature DB >> 16177333

Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh.

Firdausi Qadri1, Ann-Mari Svennerholm, Sohel Shamsuzzaman, Taufiqur Rahman Bhuiyan, Jason B Harris, A N Ghosh, G Balakrish Nair, Andrej Weintraub, Shah M Faruque, Edward T Ryan, David A Sack, Stephen B Calderwood.   

Abstract

Vibrio cholerae O139 emerged in 1992 as a major cause of epidemic cholera. However, the incidence of disease due to this new serogroup subsequently decreased for almost a decade. In April 2002, there was a dramatic resurgence of V. cholerae O139 in Bangladesh. We compared the phenotypic properties of the bacterial isolates and the immunological responses in patients with disease due to V. cholerae O139 during the 2002 epidemic with those dating to the emergence of this disease in 1993 to 1995. Strains isolated from patients in the two time periods were compared with respect to capsular polysaccharide, their resistance to the bactericidal effect of serum, and their capacity to be used as target strains in complement-mediated vibriocidal assays. Phase-contrast microscopy showed that strains isolated in 2002 had less capsular material than those isolated from 1993 to 1995 (P = <0.001), a finding confirmed by electron microscopic studies. Strains isolated in 2002 were more susceptible to the bactericidal activity of serum compared to strains from 1993 to 1995 (P = 0.013). Compared to results using a standard O139 strain, a modified vibriocidal assay utilizing a 2002 strain, CIRS 134, as the target organism detected higher vibriocidal responses in both O139-infected cholera patients as well as O139 vaccine recipients. The vibriocidal assay utilizing the less encapsulated 2002 strain, CIRS 134, is a more sensitive indicator of adaptive immune responses to recent infection with V. cholerae O139. Consequently, this assay may be useful in studies of both O139-infected patients and recipients of O139 vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177333      PMCID: PMC1230989          DOI: 10.1128/IAI.73.10.6577-6583.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.

Authors:  M Jertborn; A M Svennerholm; J Holmgren
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

Review 2.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

3.  Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India.

Authors:  T Ramamurthy; S Garg; R Sharma; S K Bhattacharya; G B Nair; T Shimada; T Takeda; T Karasawa; H Kurazano; A Pal
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

4.  Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.

Authors:  J G Morris; G E Losonsky; J A Johnson; C O Tacket; J P Nataro; P Panigrahi; M M Levin
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

5.  The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants.

Authors:  M K Waldor; R Colwell; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

6.  Role of Shigella dysenteriae type 1 slime polysaccharide in resistance to serum killing and phagocytosis.

Authors:  F Qadri; M A Haque; A Hossain; T Azim; K Alam; M J Albert
Journal:  Microb Pathog       Date:  1993-06       Impact factor: 3.738

7.  Encapsulation of Streptococcus uberis: influence of storage and cultural conditions.

Authors:  K R Matthews; B M Jayarao; A J Guidry; E F Erbe; W P Wergin; S P Oliver
Journal:  Vet Microbiol       Date:  1994-04       Impact factor: 3.293

8.  Comparison of Vibrio cholerae O139 with V. cholerae O1 classical and El Tor biotypes.

Authors:  K E Calia; M Murtagh; M J Ferraro; S B Calderwood
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

9.  Development and evaluation of rapid monoclonal antibody-based coagglutination test for direct detection of Vibrio cholerae O139 synonym Bengal in stool samples.

Authors:  F Qadri; A Chowdhury; J Hossain; K Chowdhury; T Azim; T Shimada; K M Islam; R B Sack; M J Albert
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

10.  The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1.

Authors:  L E Comstock; D Maneval; P Panigrahi; A Joseph; M M Levine; J B Kaper; J G Morris; J A Johnson
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

View more
  7 in total

1.  Crystal structure of the full-length ATPase GspE from the Vibrio vulnificus type II secretion system in complex with the cytoplasmic domain of GspL.

Authors:  Connie Lu; Konstantin V Korotkov; Wim G J Hol
Journal:  J Struct Biol       Date:  2014-08-01       Impact factor: 2.867

2.  Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.

Authors:  Young Ok Baik; Seuk Keun Choi; Jae Woo Kim; Jae Seung Yang; Ick Young Kim; Chan Wha Kim; Jang Hee Hong
Journal:  J Korean Med Sci       Date:  2014-04-01       Impact factor: 2.153

3.  Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.

Authors:  Maria Rosario Z Capeding; Maria Liza Antoinette M Gonzales; Mandeep Singh Dhingra; Naveena Aloysia D'Cor; Venkat Jayanth Midde; Badri Narayan Patnaik; Yaël Thollot; Eric Desauziers
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 4.  Immunomodulatory Roles of Polysaccharide Capsules in the Intestine.

Authors:  Samantha A Hsieh; Paul M Allen
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

5.  A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.

Authors:  Dilip Mahalanabis; Anna Lena Lopez; Dipika Sur; Jacqueline Deen; Byomkesh Manna; Suman Kanungo; Lorenz von Seidlein; Rodney Carbis; Seung Hyun Han; Seong Hye Shin; Stephen Attridge; Raman Rao; Jan Holmgren; John Clemens; Sujit K Bhattacharya
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

6.  A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.

Authors:  Paola Russo; Antonio D Ligsay; Remigio Olveda; Seuk Keun Choi; Deok Ryun Kim; Ju Yeon Park; Ju Yeong Park; Khalid Ali Syed; Ayan Dey; Yang Hee Kim; Sung Hee Lee; Jayoung Kim; Yun Chon; Laura Digilio; Chan Wha Kim; Jean-Louis Excler
Journal:  Vaccine       Date:  2018-06-09       Impact factor: 3.641

7.  Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.

Authors:  Mohammad Kamruzzaman; Meagan Kelly; Pavol Kováč; Peng Xu; Edward T Ryan; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Aklima Akter; Rajib Biswas; M Hasanul Kaisar; Taufiqur R Bhuiyan; Louise C Ivers; Ralph Ternier; Jean-Gregory Jerome; Hélene B Pfister; Xiaowei Lu; Sameh E Soliman; Bart Ruttens; Rina Saksena; Jana Mečárová; Alžbeta Čížová; Firdausi Qadri; Slavomír Bystrický
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.